{
  "pmcid": "12443838",
  "sha256": "cbcb633eec8c9bd387ac39f420774fc8d9bd59a87bce58419fd23fad2fa04951",
  "timestamp_utc": "2025-11-09T15:42:05.173615+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.597684923771883,
    "reading_ease": 16.473500846979135,
    "word_count": 322
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Design: A prospective, randomized, controlled, single-blind study."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants: A total of 100 patients classified as ASA physical status II–III who were scheduled for thoracoscopic surgery were enrolled."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Interventions: Participants were randomly allocated to receive either LB or conventional bupivacaine hydrochloride via intercostal nerve block, performed under ultrasound guidance."
      },
      "Objective": {
        "score": 1,
        "evidence": "Objective: This study aimed to evaluate and compare the analgesic efficacy of liposomal bupivacaine (LB) versus conventional bupivacaine hydrochloride for intercostal nerve block after thoracoscopic surgery."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was postoperative pain intensity assessed using the Visual Analog Scale (VAS; 0–10) both at rest and during exercise at 6, 8, 12, 24, 48, and 72 h after surgery."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Participants were randomly allocated to receive either LB or conventional bupivacaine hydrochloride."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Design: A prospective, randomized, controlled, single-blind study."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Participants: A total of 100 patients classified as ASA physical status II–III who were scheduled for thoracoscopic surgery were enrolled."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Compared with conventional bupivacaine, the LB group showed significantly lower VAS scores at rest and during exercise at all six postoperative time points (6–72 h; all p < 0.01)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Safety outcomes included the incidence of postoperative nausea and vomiting (PONV), pruritus, pulmonary complications, and cardiovascular events."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Clinical trial registration: www.chictr.org.cn , ChiCTR2300076708."
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 16,
    "max_score": 25
  }
}